Connect your AI

Royalty Pharma RPRX Total Current Assets

Total Current Assets at other companies

Ligand PharmaceuticalsLGND

$865.42M+180%

BridgeBio PharmaBBIO

$1.24B+78.6%

Rigel PharmaceuticalsRIGL

$234.03M+59.7%

Roivant SciencesROIV

$5.17B+3.3%

ALN

Alnylam PharmaceuticalsALNY

$4.62B+26.8%

Ionis PharmaceuticalsIONS

$2.49B-3.3%

Other financials

Income statement

Revenue$630.6M+11.0%

Operating income$563.0M+5.4%

Net income$294.7M+23.1%

EPS (diluted)$0.67+21.8%

Balance sheet

Cash & equivalents$586.4M-46.1%

Total debt$9.0B+17.8%

Total equity$9.9B+1.6%

Total assets$19.8B+12.5%

Cash flow

Operating cash flow$718.2M+20.5%

Valuation

Market cap$26.58B+69.3%

Enterprise value$34.97B+51.4%

P/E32.1×+16.8×

P/S10.9×+4.1×

Profitability

Operating margin65.1%-18.9pp

Net margin33.9%-14.4pp

Returns & leverage

Return on equity8.4%-2.7pp

Debt / equity0.9×+0.1×

Current ratio2.7×+1.1×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept us-gaap:AssetsCurrent.

The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Royalty Pharma's total current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Royalty Pharma's total current assets?: Royalty Pharma (RPRX) reported total current assets of $1.43B in Q1 2026.
How has Royalty Pharma's total current assets changed year-over-year?: Royalty Pharma's total current assets decreased by 22.6% year-over-year, from $1.84B to $1.43B.
What is the long-term trend for Royalty Pharma's total current assets?: Over 5 years (2020 to 2025), Royalty Pharma's total current assets has grown at a -10.7% compound annual growth rate (CAGR), from $2.7B to $1.53B.
What does total current assets mean?: The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.